Dr. Mims Discusses Momelotinib in Myelofibrosis

Alice S. Mims, MD
Published Online: Friday, Nov 10, 2017



Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

The SIMPLIFY-1 study investigated momelotinib to determine if it was non-inferior to ruxolitinib (Jakafi). It did show non-inferiority of splenic size for patients with myelofibrosis, states Mims.

The SIMPLIFY-2 attempted to determine if momelotinib was superior to ruxilitinib. It was not superior but there was improvement in anemia. There will be some role for momelotinib in the future for these patients, states Mims.
 


Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

The SIMPLIFY-1 study investigated momelotinib to determine if it was non-inferior to ruxolitinib (Jakafi). It did show non-inferiority of splenic size for patients with myelofibrosis, states Mims.

The SIMPLIFY-2 attempted to determine if momelotinib was superior to ruxilitinib. It was not superior but there was improvement in anemia. There will be some role for momelotinib in the future for these patients, states Mims.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x